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ABSTRACT
Cardiac structure and function are affected both by acromegaly and
hyperthyroidism. Whereas the former is mainly characterized by ven-
tricular hypertrophy as well as diastolic and systolic impairment, the
latter frequently leads to increased heart rate and enhancement of
contractility and cardiac output.
To further investigate this issue, we designed this two-arm study.
In the first cross-sectional study, we compared echocardiography and
radionuclide angiography results obtained in eight hyperthyroid ac-
romegalic patients, eight hyperthyroid nonacromegalic patients, and
eight healthy subjects. All acromegalic patients were receiving treat-
ment for acromegaly at the onset of hyperthyroidism. In the second
longitudinal study, performed in the group of acromegalic patients,
we compared the cardiovascular results obtained during hyperthy-
roidism with the retrospective data obtained at the initial diagnosis
of acromegaly and after 1-yr treatment for this disease and those
prospective data obtained during the remission of hyperthyroidism.
In the cross-sectional study, hyperthyroid acromegalic patients
showed an increase in the left ventricular (LV) mass index (LVMi)
compared to healthy and hyperthyroid controls (P , 0.05), with ev-
idence of LVMi hypertrophy in five of them (62.5%). A significant
correlation was found between LVMi and GH levels (r 5 0.785; P ,
0.05). The LV ejection fraction (LVEF) at rest was higher in the control
hyperthyroid population than in healthy controls (P , 0.05), whereas
the LVEF response to exercise was reduced in acromegalic patients
(P , 0.05 vs. healthy controls). In acromegalics, the exercise-induced
change in LVEF was significantly reduced compared to that in
healthy controls (P , 0.001), but not to that in hyperthyroid controls
(P , 0.07), being abnormal (,5% increase vs. baseline values) in six
patients. Four of these six patients (66%) had elevated GH and in-
sulin-like growth factor I levels during the treatment of acromegaly.
An inverse correlation between GH and LVEF at rest (r 5 20.896; P ,
0.05) and at peak exercise (r 5 20.950; P , 0.001) was recorded. The
peak filling rate was reduced in hyperthyroid acromegalic patients
compared to those in both control populations (P , 0.05).
In the longitudinal study, acromegalic patients showed an in-
creased LVMi during hyperthyroidism compared to that observed
after successful treatment of acromegaly (P , 0.05); resting LVEF
was increased compared to both basal (P , 0.001) and posttreatment
values (P , 0.05). However, the exercise-induced change in LVEF was
reduced (P , 0.05 vs. previous follow-up values). Remission of hy-
perthyroidism led to significant reduction of LVMi (P , 0.05) and
resting LVEF (P , 0.05) and an increase in exercise-induced LVEF
(P , 0.05).
In light of these findings, hyperthyroidism produces a detrimental
effect on the cardiovascular system of acromegalic patients, partic-
ularly in those with uncontrolled disease. Thus, control of GH and
insulin-like growth factor I should be a major objective, as cardio-
vascular risk persists in patients with ineffective hormonal suppres-
sion, and constant endocrine and cardiovascular surveillance remain
crucial steps in patient follow-up. (J Clin Endocrinol Metab 85: 1426–
1432, 2000)
ENDOCRINE-RELATED cardiovascular disorders, eitherstructural or functional, have long been recognized in
acromegaly and hyperthyroidism, and their progression has
been extensively studied (1–6). In acromegaly, cardiac in-
volvement is considered a major determinant for patients’
morbidity, and it increases the mortality rate (4, 7–10). A
proposed sequence of events (5) infers that, initially, low
systemic vascular resistance and high diastolic capacity may
enhance the cardiac output and cause concentric cardiac
hypertrophy in acromegaly. Subsequently, diastolic compe-
tence impairs and gives rise to systolic complications (11–16),
so that unless effective suppression of GH and insulin-like
growth factor I (IGF-I) is achieved, cardiac output may grad-
ually decline and predispose to congestive heart failure (5).
Furthermore, concomitant disorders, such as arterial hyper-
tension, coronary artery disease, and ventricular arrhythmia,
are able to worsen the prognosis (5, 15).
Similarly, thyrotoxicosis can play per se a key role in car-
diac performance. The effects of thyroid hormones are
prompt on both heart contractility and systemic vascular
system. In these conditions, increased heart rate, reduction of
systemic vascular resistance, and enhancement of diastolic
function have been reported (6, 17–22). These factors con-
tribute to increase the preload and the cardiac output (6).
When prolonged, this condition may impair ventricular fill-
ing capacities and induce cardiac failure (18–25), which can
be accelerated by aging and preexisting cardiovascular dis-
orders (17, 19, 25).
Accordingly, we investigated the hypothesis that the con-
comitant presence of acromegaly and hyperthyroidism could
enhance the risk of developing cardiovascular complications.
This objective was supported by the demonstration that thy-
roid disorders can frequently occur in acromegalic patients;
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goiter is recorded in up to 92% (7, 26–29) and hyperthyroid-
ism in 3.5–26% of cases (7, 26, 28).
This report describes the changes in cardiac structure and
function in eight patients who developed hyperthyroidism
after acromegaly. The development of thyrotoxicosis repre-
sented a worsening of both cardiac hypertrophy and diastolic
and systolic function.
Subjects and Methods
Patients
In 1990 we started a program of cardiological evaluation in all patients
admitted to our department for pituitary tumors. Among 93 patients
with acromegaly admitted between 1990 and 1999, 10 (10.7%) developed
hyperthyroidism after the initial diagnosis of acromegaly, but 8 (8.6%;
6 women and 2 men; age, 53 6 5 yr; mean 6 sem) had complete hormone,
echocardiography, and gated blood pool radionuclide angiography
records and constituted the study population. Disease duration was
deduced by the patient’s clinical history and photograph records; in this
series it was 17 6 3 yr. Hyperthyroidism was diagnosed on the basis of
clinical features, elevated free thyroid hormone levels, and suppressed
TSH levels. No patient had previously received thyroid hormone sup-
plementation. No iodine had been administered for diagnostic/thera-
peutic procedures within the previous 6 months. All acromegalic pa-
tients developed hyperthyroidism after the diagnosis and treatment of
acromegaly. The presumed interval occurring between the onset of
hyperthyroidism and diagnosis was 6.7 6 0.7 months. The study was
approved by the local ethics committee, and all patients gave informed
consent to participate.
Study design
To address the role of hyperthyroidism in acromegalic cardiomyop-
athy, the study was designed in two arms: a cross-sectional study aimed
at comparing the results of the patient group with those obtained in 8
age- and sex-matched healthy controls free of thyroid disorders and in
8 nonacromegalic hyperthyroid patients. In these 24 subjects endocrine
evaluation of pituitary and thyroid hormones, echocardiography, and
gated blood pool radionuclide angiography were carried out. A longi-
tudinal study was performed in the group of acromegalic patients by
comparing the data obtained retrospectively in patients when they re-
ceived the initial diagnosis of acromegaly (study 0) with those obtained
respectively after 1 yr of treatment for this disease (study 1), when they
received diagnosis of hyperthyroidism (study 2), and after 6–8 months
of biochemical remission of hyperthyroidism (study 3).
Hormonal assessment and thyroid evaluation
Hormonal profiles included assay of GH (calculated as the mean of
three consecutive samples drawn at 15-min intervals), ethanol-extracted
IGF-I, free T4 (fT4) and T3 (fT3), and TSH levels in the basal condition and
when suppressed after 200-mg iv TRH injection (TSH peak normal when
.3 mIU/mL). Assay of anti-TSH receptor antibodies was performed
when Graves’ disease was suspected. As cure criteria for acromegaly,
fasting GH values below 2.5 mg/L and/or glucose-suppressed GH levels
below 1 mg/L together with normal IGF-I values for age were taken into
consideration (3); biochemical remission of hyperthyroidism was con-
sidered when normalization of fT3 and fT4 levels as well as restoration
of normal TSH secretion was obtained. All hormonal profiles were
assessed by immunoradiometric assay, using commercially available
kits. Normal IGF-I ranges in our laboratory in 20- to 30-, 31- to 40-, 41-
to 50-, and over 50-yr-old subjects were 110–502, 100–494, 100–303, and
78–258 mg/L. Normal ranges for fT3, fT4, and TSH were, respectively,
1.6–3.4 pg/mL, 7.1–18.5 pg/mL, and 0.5–4.7 mU/mL. Thyroid mor-
phology was investigated by means of ultrasonography and 99Tc
scintigraphy.
Cardiovascular evaluations
A preliminary exercise electrocardiogram and thallium-201 myocar-
dial scintigraphy excluded concomitant coronary arterieal disease in
patients who had experienced chest pain resembling angina pectoris.
Patients received a careful physical examination at each step of the
study. Assessment of the cardiovascular morphology by M- and B-mode
Doppler echocardiography and of cardiac function by measuring left
ventricular ejection fraction and assessment of peak filling rate by gated
blood pool radionuclide angiography were performed in all subjects.
Radionuclide angiography was chosen as a useful operator-independent
method to study left ventricle performance, because it can provide direct
and objective evaluation of ventricular function.
Echocardiography
All subjects were studied when lying in the left lateral recumbent
position after a 10-min resting period, according to the recommenda-
TABLE 1. Individual patients’ data at diagnosis of hyperthyroidism
Sex/age (yr) Duration ofacromegaly (yr)
GH
(mg/L)
IGF-I
(mg/L) Treatment of acromegaly
Duration of
hyperthyroidism
(months)
Treatment of
hyperthyroidism
F, 25 4 0.8 210 Surgery, radiotherapy 7 Methimazole
F, 46 7 1.7 219 Octreotide 5 Methimazole
F, 46 18 6.9 246 Octreotide 8 Methimazole
M, 50 11 4.7 291 Surgery, radiotherapy, octreotide 4 Methimazole
F, 52 19 4.2 421 Surgery, octreotide 6 Methimazole
F, 64 30 1.8 187 Surgery, octreotide 8 Methimazole
F, 67 25 2.1 250 Octreotide 10 Methimazole, radioiodine
M, 74 22 8.5 375 Octreotide 6 Methimazole, radioiodine
TABLE 2. Hormonal data in acromegalic patients evaluated at diagnosis of acromegaly, after 1 yr of treatment, at diagnosis of
hyperthyroidism, and after 6–8 months of biochemical remission of hyperthyroidism
Serum GH
levels (mg/L)
Plasma IGF-I
levels (mg/L)
Serum fT3
levels (pg/mL)
Serum fT4
levels (pg/mL)
Serum TSH levels
(mIU/mL)
At diagnosis of acromegaly 32.9 6 9 589 6 47 2.2 6 0.2 10 6 0.5 1.4 6 0.3
After 1 yr of treatment 2.4 6 0.5a 283.1 6 36.5a 2.6 6 0.7 11.5 6 1.5 1.2 6 0.3
At diagnosis of hyperthyroidism 3.5 6 1 274.8 6 29.3 9.1 6 1.2b 25.2 6 2.1b 0.07 6 0.01b
During remission of hyperthyroidism 3.8 6 1 281 6 37.4 2.9 6 0.3c 11.5 6 1.6c 1.9 6 0.2c
For individual P value, see the text.
a Euthyroid patients in remission vs. baseline values.
b Hyperthyroid acromegalic patients vs. values of euthyroid acromegaly in remission.
c Hyperthyroid patients in remission vs. active hyperthyroidism.
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tions provided by the American Society of Echocardiography (30). A
complete M-mode, two-dimensional analysis was performed using an
ultrasound mechanical system equipped with 3.5 MHz transducer (Apo-
gee CX, Interspec, Ambler, PA), and evaluation of left ventricle mass was
obtained using Devereux’s formula during the M-mode measurement,
according to Penn’s convention (31). Left ventricle hypertrophy was
considered when left ventricular myocardial mass, corrected for the
body surface area (LVMi), was greater than 135 g/m2 in males and 110
g/m2 in females (31).
Radionuclide angiography
The study was performed at rest and after exercise and was accom-
panied by measurements of heart rate and blood pressure as previously
reported in detail (16). The procedure of in vivo labeling of red blood cells
was performed with 555 MBq (15 mCi) of 99 mTc. Acquisition was
performed at rest and during dynamic physical exercise in the 45° left
anterior projection with a 15° craniocaudal tilt, with the patient in the
supine position, using a small field of view g-camera (Starcam 300 A/M,
General Electric, Milwaukee, WI) and a low energy collimator. Data
were recorded at a rate of 30 frames/cardiac cycle for the resting study
and 16 frames/cardiac cycle for the exercise study on a dedicated com-
puter system (General Electric). At least 200,000 counts/frame were
acquired. Exercise studies were performed using a bicycle ergometer
with a restraining harness to minimize the patient’s motion under the
camera. Exercise loads were increased by 25 watts every 2 min up to
submaximal exercise. Radionuclide angiography studies were analyzed
using a standard commercial software system (General Electric). Left
ventricular regions of interests were automatically drawn for each
frame, and a background region of interest was also computer delin-
eated on the end-systolic frame. After background correction, a left
ventricular time-activity curve was generated. Indexes of left ventricular
function were derived by computer analysis of the background-cor-
rected time-activity curve. The ejection fraction (EF) was computed
relatively to end-diastolic and end-systolic counts. Peak left ventricular
ejection and filling rates were also calculated after a Fourier expansion
with four harmonics. The peak ejection rate was computed as the min-
imum negative peak before end-systole, and the peak filling rate (PFR)
was calculated as the maximum positive peak after end-systole on the
first derivative of the left ventricular time-activity curve. Both peak
ejection rate and PFR were computed as left ventricular counts per s,
normalized for the number of counts at end-diastole and expressed as
end-diastolic volume per s; to minimize the influence of the ejection
fraction, the PFR was also expressed relative to the left ventricular stroke
volume and as the ratio of PFR to peak ejection rate (32). Time to peak
ejection rate was determined from the R wave, and time to peak filling
rate was determined relative to end systole (minimal volume on the
time-activity curve).
Statistical analysis
Data are the mean 6 sem; one-way ANOVA, followed by Newman-
Keuls test, was employed for comparison among acromegalic patients
in hyperthyroidism with healthy and hyperthyroid controls (cross-sec-
tional study) and with remaining follow-up evaluations (longitudinal
study), applying Bonferroni’s correction. Pearson’s analysis was used to
correlate cardiovascular results with hormonal data during the different
intervals in acromegalic patients’ group. P , 0.05 was considered sta-
tistically significant.
Results
Clinical and hormonal data
Patients’ data are included in Tables 1 and 2, respectively.
At the time of diagnosis of hyperthyroidism, one patient had
been cured of acromegaly after surgery and radiotherapy. Of
the remaining seven patients, all were subjected to chronic sc
octreotide treatment, and normal GH and IGF-I levels were
recorded in three of them (43%). Two patients suffered from
FIG. 1. Individual data and mean 6
SEM values of LVMi in hyperthyroid ac-
romegalic patients compared to healthy
control subjects and hyperthyroid con-
trol subjects (cross-sectional study).
TABLE 3. Hemodynamic parameters, left ventricular functional,
and morphological data for healthy controls subjects, hyperthyroid
control patients, and hyperthyroid acromegalic patients
Parameters
Healthy
control
subjects
Hyperthyroid
control
patients
Hyperthyroid
acromegalic
patients
P
HR (beats/min)
r 73.4 6 2.6 104 6 5.1a 111.7 6 6.2a 0.001
e 139.1 6 3.9 151.7 6 4a 156.3 6 7.1a NS
SBP (mm Hg)
r 118.6 6 2 122.3 6 3.1 131.1 6 6.3 NS
e 148.7 6 1.9 151 6 4.8 153.4 6 6 NS
DBP (mm Hg)
r 83.6 6 4.1 87.1 6 2.2 97.1 6 3.9a,b 0.05
e 107.3 6 2.9 109 6 3.2 114.1 6 3.1 NS
LVMi (g/m2)
r 82.5 6 5.3 102.1 6 7.5a 128.6 6 12a,b 0.05
LV EF (%)
r 62.7 6 2.4 69.1 6 1.7a 67.5 6 2.5 NS
e 75.8 6 3.2 66.1 6 1.6a 58 6 4.4a 0.05
DEF 20.1 6 2.2 24.7 6 2.1a 214.5 6 4.7a 0.001
PER (EDV/s)
e 3.5 6 0.2 3.5 6 0.1 3.4 6 0.2 NS
PFR (EDV/s)
r 3.3 6 0.2 3.8 6 0.2 2.4 6 0.2a,b 0.001
PFR (SV/s)
r 4.1 6 0.3 4.1 6 0.3 3 6 0.2a 0.05
PFR/PER
r 0.94 6 0.1 1.1 6 0.1 0.74 6 0.1 NS
EC (watts)
e 118 6 4.1 84.3 6 8.1a 65.6 6 7.1a,b 0.001
ED (min)
e 9.3 6 0.3 7.9 6 0.4a 6.3 6 0.2a,b 0.001
For abbreviations of cardiovascular parameters, see the text. r and
e indicate resting and exercise testing, respectively. Individual P
values are reported in the text.
a Significant vs. healthy control subjects.
b Significant vs. hyperthyroid control patients.
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both arterial hypertension and glucose intolerance, one from
hypertension, and another from diabetes mellitus. Hyper-
thyroidism presented with clinical and biochemical features
suggestive of Graves’ disease in four patients (50%), showing
elevated Tr-Ab levels (in all) or ophthalmopathy (in three
patients). Multinodular goiter with elevated uptake at scin-
tigraphy was documented in two of them and in all of the
remaining patients. Diastolic blood pressure at rest was
higher (P , 0.05) in hyperthyroid acromegalic patients than
in healthy controls. Heart rate was significantly higher in
hyperthyroid acromegalic than in healthy controls both at
rest (P , 0.001) and after exercise (P , 0.05), due to the
presence of overt tachyarrhythmia in four and atrial fibril-
lation in two patients, and supplementation with b-adren-
ergic antagonists was provided after they had completed the
cardiological evaluation.
Methimazole was employed as a therapeutic approach to
hyperthyroidism in six patients, followed by conventional
radioiodine in the remaining two, and after 6–8 months,
normal fT3 (P , 0.05), fT4 (P , 0.05), and TSH (P , 0.001)
levels were found. Heart rate was significantly reduced both
at rest (P , 0.001) and after exercise (P , 0.05), and it was
normalized in all patients except in one of the two patients
suffering from atrial fibrillation. No significant change in
blood pressure was recorded.
Cardiovascular data
Cross-sectional study (Table 3). LVMi values were significantly
higher in the group of the hyperthyroid acromegalic patients
than in either healthy subjects or control hyperthyroid pop-
ulation (P , 0.05 in both cases; Fig. 1). During hyperthy-
roidism, echocardiographic evidence of LV hypertrophy was
detected in five acromegalic patients (62.5%; no. 2–5 and 8;
Figs. 1 and 2), four of whom (80%) showed elevated GH
levels despite being subjected to chronic octreotide treat-
ment. LVMi was higher in patients with elevated GH levels
than in patients showing GH suppression (157.2 6 7.2 vs.
97.2 6 6.2 g/m2; P , 0.001) at the onset of hyperthyroidism.
As a consequence, a significant correlation was observed
between GH levels and LVMi (r 5 0.785; P , 0.05).
Compared to healthy subjects, resting LVEF was signifi-
cantly higher in hyperthyroid controls (P , 0.05) and hy-
perthyroid acromegalic patients, although it did not reach
statistical significance (Fig. 3). By contrast, an abnormal
LVEF response to exercise (,5% increase vs. baseline values)
was observed in six acromegalic patients, among whom four
(66%) had unsuppressed GH levels. In these four patients,
the LVEF response to exercise was significantly lower than
that in patients with suppressed GH during therapy (49.2 6
4.7% vs. 64.2 6 3.8%; P , 0.05). With respect to the healthy
population, the EF response to exercise was reduced in both
acromegalic patients and hyperthyroid patients (P , 0.05 in
both cases; Fig. 3). The exercise-induced change in LVEF (D
LVEF) was significantly lower in hyperthyroid acromegalic
patients than in healthy controls (P , 0.001), but not in
hyperthyroid controls (P , 0.07; Fig. 3). In the group of
hyperthyroid acromegalic patients, a significant correlation
was found between GH values and LVEF at rest (r 5 20.896;
P , 0.05), at peak exercise (r 5 20.950; P , 0.001), and as D
LVEF (r 5 20.888; P , 0.05). D LVEF was correlated with PFR
at rest (r 5 0.740; P , 0.05). PFR was significantly lower in
the patient population compared with those in healthy and
hyperthyroid controls (P , 0.05 and , 0.001, respectively)
and inversely correlated with age (r 5 20.718; P , 0.05) and
disease duration (r 5 20.745; P , 0.05). Hyperthyroid status
exerted a precocious muscular exhaustion in acromegalic
FIG. 2. Individual data of LVMi in acromegalic patients during the
different follow-up evaluations (longitudinal study). Patients are
numbered as described in the text.
FIG. 3. Mean 6 SEM values of LVEF in the resting condition (top), at
peak exercise (middle), and as exercise-induced change (D LVEF;
bottom) in hyperthyroid acromegalic patients compared to healthy
control subjects and hyperthyroid control subjects (cross-sectional
study).
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patients, with reduced exercise capacity and duration com-
pared with both healthy controls (P , 0.05 and , 0.001) and
control hyperthyroid patients (P , 0.05). Remarkably, three
acromegalic patients precociously concluded their workout
due to muscular exhaustion.
Longitudinal study (Table 4). In study 2, LVMi values were
higher than those in study 1 (P , 0.05), whereas LVMi values
were lower compared to data recorded in study 0 (P , 0.05;
Fig. 2). A direct correlation was found between LVMi values
obtained in study 0 and those recorded in study 2 (r 5 0.705;
P , 0.05). Resting LVEF was significantly enhanced com-
pared to both previous follow-up values (P , 0.001 and 0.05,
respectively), but the response to exercise was impaired, and
the D LVEF was lower compared to values recorded in study
1 (P , 0.05 and 0.001, respectively; Fig. 4). Additionally,
exercise capacity and duration were reduced compared to
results obtained during study 1 (P , 0.05 in both cases). The
achievement of euthyroidism (study 3) was followed by a
significant reduction of LVMi (P , 0.05) in all patients, and
a normalization of LVMi was observed in one patient (no. 2,
Fig. 2). A prompt improvement of cardiac performance at
peak exercise was similarly obtained, with an increase in
LVEF at peak exercise as well as in D LVEF (P , 0.05 in both
cases; Fig. 4). An exercise-induced change in LVEF was cor-
related to PFR (r 5 0.780; P , 0.05). Additionally, exercise
capacity and duration improved (P , 0.05 in both cases).
Discussion
Cardiovascular disorders associated with both acromeg-
aly and hyperthyroidism have been extensively studied, and
they are known to progressively lead to structural and func-
tional impairment of the heart (1–6). The evaluation of car-
diac morphology and function in eight thyrotoxic acrome-
galic patients showed an increase in the left ventricular mass
and a reduction of cardiac performance during physical ex-
ercise. Cardiac performance was enhanced in resting condi-
tions, as shown in control hyperthyroid patients, but an
impaired response at peak exercise and a premature mus-
cular exhaustion were observed, probably as a result of the
reduced functional reserve. Additionally, tachyarrhythmia
or atrial fibrillation was observed. Hyperthyroidism exerted
a detrimental effect that was more evident in patients failing
to achieve GH and IGF-I suppression. These results taken
together suggest an enhanced cardiovascular risk when ac-
romegaly is complicated with hyperthyroidism, especially in
patients with persistently elevated GH and IGF-I levels.
Although a limited number of investigations of the coex-
istence of acromegaly and hyperthyroidism currently exist
(7, 26, 28), growing evidence has accumulated that the thy-
roid can be enlarged in up to 92% of acromegalic patients
(26–29), independently of TSH levels (28, 33). Data concern-
ing the prevalence of hyperthyroidism in the setting of ac-
romegaly are not uniform, as it was reported to range be-
tween 3.5–26% (7, 26, 28). In our experience, 9 patients
TABLE 4. Hemodynamic parameters, left ventricular functional, and morphological data for acromegalic patients at different follow-up
evaluations
Parameters Study 0 Study 1 P Study 2 Study 3 P
HR (beats/min)
r 76 6 3.1 73.9 6 2 NS 111.7 6 6.2a,b 71.1 6 4.1 0.001
e 136.7 6 3.9 129.6 6 4.9 NS 156.3 6 7.1a,b 124.1 6 3.3 0.05
SBP (mm Hg)
r 128.8 6 4.2 124.2 6 4.1 NS 131.1 6 6.3 125.9 6 4.9 NS
e 149.6 6 6.6 146 6 5.9 NS 153.4 6 6 149 6 3.7 NS
DBP (mm Hg)
r 94.6 6 3 90.2 6 3 NS 97.1 6 3.9 93.4 6 2.1 NS
e 111.6 6 4.1 107 6 3.3 NS 114.1 6 3.1 109.4 6 3.6 NS
LVMi (g/m2)
r 142 6 11.2 121 6 12.1 0.05 128.6 6 12a,b 120.4 6 11.5a 0.05
LV EF (%)
r 53.1 6 3 60.1 6 2.8 0.05 67.5 6 2.5a,b 58.6 6 1.6a 0.05
e 51.6 6 2.7 64.6 6 2.2 0.05 58 6 4.4b 61.5 6 2a 0.05
DEF 22.1 6 4.4 8.1 6 2.9 0.05 214.5 6 4.7a,b 4.8 6 1.7a 0.05
PER (EDV/s)
e 3.6 6 0.3 3.5 6 0.3 NS 3.4 6 0.2 3.2 6 0.2 NS
PFR (EDV/s)
r 2.7 6 0.2 3.1 6 0.3 NS 2.4 6 0.2 2.9 6 0.3 NS
PFR (SV/s)
r 3.2 6 0.4 3.8 6 0.2 NS 3 6 0.2b 3.8 6 0.1 0.05
PFR/PER
r 0.77 6 0.1 0.87 6 0.1 NS 0.74 6 0.1 0.9 6 0.1 NS
EC (watts)
e 84.3 6 8.1 96.8 6 9.9 NS 65.6 6 7.1b 93.7 6 10.3 0.05
ED (min)
e 7.1 6 0.9 8.4 6 0.6 NS 6.3 6 0.2b 8.1 6 0.7 0.05
For abbreviations of cardiovascular parameters, see the text. r and e indicate resting and exercise testing, respectively. Study 0, Patients
at diagnosis of active acromegaly; study 1, patients after treatment of acromegaly; study 2, patients at the onset of hyperthyroidism; study 3,
patients after achieving hyperthyroidism remission. Individual P values are reported in the text.
a Significant vs. study 0.
b Significant vs. study 1.
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presenting hyperthyroidism after having received a diagno-
sis of acromegaly and 1 other patient coming to our attention
with both diseases concomitantly accounted for a prevalence
of 10.7%. Of these 10 patients, 8 were included in the present
study and were receiving treatment for acromegaly at the
onset of hyperthyroidism. In particular, 1 patient had been
cured by surgery and radiotherapy, whereas the remaining
7 were subjected to chronic octreotide therapy. Whether oc-
treotide treatment could have triggered thyroid hyperfunc-
tion is difficult to estimate. Neither previous report supports
this evidence (26–29). Instead, it has been proposed that
chronic GH and IGF-I excess could stimulate the thyroid to
develop morphological and functional changes, in a fashion
that would be TSH independent (26–29). Therefore, in our
series of hyperthyroid acromegalic patients, hyperthyroid-
ism seems to have occurred as a complication in the natural
course of acromegaly itself. Among our patients, biochemical
and clinical features suggestive of Graves’ disease were
present in 4 subjects, 2 of whom showed ultrasonographic
and scintigraphic features of toxic multinodular goiter, at
variance with the classical presentation of Graves’ disease
(34). All of the remaining hyperthyroid patients had toxic
multinodular goiter.
The majority of our patients exhibited signs and symptoms
of cardiovascular involvement. In acromegaly, heart disor-
ders are prominent factors in rising morbidity and mortality
(7–10). Nevertheless, patients may be clinically asymptom-
atic for long, that is because cardiac impairment develops
stepwise (5). Initially, cardiac performance is increased and
predisposes to concentric myocardial hypertrophy. This, in
turn, weakens diastolic filling and impairs systolic perfor-
mance (5, 11–16), although other complications, such as ar-
terial hypertension, arrhythmias, and coronary artery dis-
ease, may be synergistically harmful (5, 15). It is conceivable
that unless a prompt suppression of GH and IGF-I excess is
achieved (35–37), cardiac performance may progressively
worsen, and in more advanced stage of disease, ventricular
dilatation and congestive heart failure may occur (5, 12–15).
There is general agreement, on the other hand, that cardiac
arrhythmias and hyperdynamic circulatory state are integral
parts of the hyperthyroid syndrome (19). It has been dem-
onstrated that both thyroid hormone administration and hy-
perthyroidism can be accompanied by reduced vascular re-
sistance and increased cardiac output (6, 17–21, 25). The
overall effect of these changes is to alter the loading condition
in the heart and to realize, in a sequence sharing some ho-
mology with that observed in the early stages of acromegaly
(6, 20, 22), a hyperkinetic syndrome. Although in a very
recent study the treatment with T3 was shown useful after
surgery in chilidren with congenital heart disease (40), the
hemodynamic change can contribute to cardiac hypertrophy
(6, 25). It has been shown that not only is the contractile
reserve reduced and the ejection fraction inadequate to effort
(18–20), but heart failure may also develop (19, 24, 37, 38, 39).
As aging and/or preexisting cardiac disorders have been
claimed to increase the risk of congestive heart failure during
hyperthyroidism (17, 19), it could be speculated that the
concomitant presence of acromegalic cardiomyopathy might
have accelerated cardiac impairment.
In our series of acromegalic patients, the increase in LVMi,
the enhancement of cardiac performance at rest, and the
presence of an overt failure at peak exercise were clearly
observed. Four patients, showing unsuppressed GH values
when hyperthyroidism was diagnosed, showed a significant
increase in LVMi and a significant reduction of LVEF at peak
exercise compared with patients showing controlled disease.
A positive correlation was found between GH levels and
cardiac mass, whereas they inversely correlated to the LVEF
at peak exercise. These findings are emblematic of a reduc-
tion of the functional cardiac reserve when hyperthyroidism
develops in the setting of acromegaly. As the worsening of
cardiac morphology and function is particularly evident in
patients with unsuppressed GH and IGF-I, this is indicative
of persisting cardiovascular impairment unless hormone
suppression is achieved. To this extent, effective and pro-
longed GH and IGF-I suppression undoubtedly represents a
restraining factor for the patient’s well-being. The observa-
tions presented in this report are therefore in agreement both
with data showing incomplete reversal of cardiac abnormal-
ities after recovery of acromegaly (5, 12, 13, 36) and with other
reports indicating a correlation between GH suppression and
cardiovascular performance (35) or mortality (7–10).
Although the results of this study could be biased by the
limited number of patients, any randomized or prospective
investigation seems inapplicable due to the scant prevalence
of hyperthyroidism in acromegaly. Rather, these findings
eventually support the concept that cardiovascular instabil-
FIG. 4. Individual data of LVEF in the resting condition (top), at peak
exercise (middle), and as exercise-induced change (D LVEF; bottom)
in acromegalic patients during the different follow-up evaluations
(longitudinal study). Patients are numbered as described in the text.
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ity in acromegaly, which is aggravated by the presence of
hypertension and glucose tolerance abnormalities (41), may
benefit by prompt recognition of concomitant endocrine dis-
orders and a combined curative approach. Although current
therapeutic solutions for acromegaly can lead to clinical and
cardiovascular improvement in many cases, incomplete hor-
monal suppression seems to limit further progression. Thus,
a constant surveillance of other endocrine circuits as well as
of the cardiovascular system remains a crucial step in the
follow-up of acromegalic patients.
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